NEW YORK (dpa-AFX Broker) - The Canadian bank RBC has given Carl Zeiss Med itec an "Outperform" rating with a target price of 150 euros. The Jena-based company is an innovation leader in the field of ophthalmology and also the market leader in some high-growth areas, wrote analyst Jack Reynolds-Clark in a study published on Thursday. He expects average annual earnings growth of 20 percent until 2027./ag/edh

Publication of the original study: 14.03.2024 / 00:47 / EDT

First publication of the original study: 14.03.2024 / 00:47 / EDT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------